Edwards Lifesciences Corporation $EW Shares Sold by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lowered its position in shares of Edwards Lifesciences Corporation (NYSE:EW) by 76.9% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,726 shares of the medical research company’s stock after selling 42,334 shares during the period. Los Angeles Capital Management LLC’s holdings in Edwards Lifesciences were worth $995,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Rosenberg Matthew Hamilton purchased a new stake in Edwards Lifesciences during the 2nd quarter worth $28,000. Quantbot Technologies LP purchased a new position in Edwards Lifesciences in the 1st quarter valued at about $26,000. NewSquare Capital LLC grew its stake in shares of Edwards Lifesciences by 57.8% during the second quarter. NewSquare Capital LLC now owns 366 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 134 shares in the last quarter. SouthState Corp purchased a new stake in shares of Edwards Lifesciences during the first quarter worth about $27,000. Finally, Costello Asset Management INC acquired a new position in shares of Edwards Lifesciences in the first quarter worth about $29,000. 79.46% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Weiss Ratings reissued a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, October 8th. Wall Street Zen cut Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Evercore ISI raised their price target on shares of Edwards Lifesciences from $88.00 to $92.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. BTIG Research raised shares of Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target on the stock in a report on Tuesday, July 29th. Finally, Robert W. Baird set a $83.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences has an average rating of “Moderate Buy” and a consensus price target of $91.39.

Insider Transactions at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the sale, the vice president owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Larry L. Wood sold 8,950 shares of the business’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total value of $698,637.00. Following the transaction, the insider owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 22,970 shares of company stock worth $1,862,878. Company insiders own 0.34% of the company’s stock.

Edwards Lifesciences Stock Up 0.5%

Edwards Lifesciences stock opened at $85.55 on Thursday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. Edwards Lifesciences Corporation has a one year low of $65.31 and a one year high of $87.09. The company has a 50-day simple moving average of $77.99 and a 200-day simple moving average of $77.59. The firm has a market capitalization of $49.65 billion, a P/E ratio of 12.31, a P/E/G ratio of 3.97 and a beta of 1.03.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings data on Thursday, October 30th. The medical research company reported $0.67 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.08. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. The firm had revenue of $1.55 billion for the quarter, compared to the consensus estimate of $1.49 billion. During the same period last year, the firm posted $0.67 EPS. Edwards Lifesciences’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, equities analysts expect that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.